In Brief: Thermo Cardiosystems HeartMate
This article was originally published in The Gray Sheet
Executive Summary
Thermo Cardiosystems HeartMate: Left ventricular-assist system is implanted for the first time in the U.K. as a permanent alternative to heart transplant. The procedure is the first of a "series of implants in which the electric LVAS will be used to permanently take over the pumping function of natural hearts too weak to beat adequately on their own," the company says. Woburn, Massachusetts-based Thermo Cardiosystems says it is "actively working" with FDA to begin a study of the HeartMate as a "permanent alternative to other medical treatments for patients who do not qualify for transplants." HeartMate was approved by FDA in October 1994 for use as a bridge-to-heart transplant ("The Gray Sheet" Oct. 10, 1994, p. 1)...
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: